Tralokinumab rebate agreement

Summary

The tender concerns a rebate agreement for the medicinal product Tralokinumab under an open-house procedure. All suitable pharmaceutical companies may join on uniform terms; no individual negotiations are held and no exclusivity is granted. The contract term is up to 24 months starting on 01/08/2026 and ends no later than 31/07/2028 or upon expiry of the patent/market exclusivity. The detailed participation and contract conditions must be checked in the tender documents.